Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Original Article

Diminazene Aceturate Enhances Angiotensin-Converting Enzyme 2 Activity and Attenuates Ischemia-Induced Cardiac PathophysiologyNovelty and Significance

YanFei Qi, Juan Zhang, Colleen T. Cole-Jeffrey, Vinayak Shenoy, Andrew Espejo, Mina Hanna, Chunjuan Song, Carl J. Pepine, Michael J. Katovich, Mohan K. Raizada
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.113.01337
Hypertension. 2013;62:746-752
Originally published September 11, 2013
YanFei Qi
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Zhang
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colleen T. Cole-Jeffrey
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vinayak Shenoy
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Espejo
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mina Hanna
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunjuan Song
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl J. Pepine
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Katovich
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohan K. Raizada
From the Departments of Physiology and Functional Genomics (Y.Q., C.T.C.-J., V.S., M.H., C.S., M.K.R.), Pharmacodynamics (Y.Q., J.Z., V.S., A.E., M.J.K.), and Medicine (C.J.P.), University of Florida, Gainesville, FL; and Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.Z.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Introduction
    • Material and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
    • What Is New?
    • What Is Relevant?
    • Summary
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters
Loading

Abstract

Angiotensin-converting enzyme 2 (ACE2) plays a critical role against myocardial infarction (MI). We hypothesized that activation of intrinsic ACE2 would be protective against ischemia-induced cardiac pathophysiology. Diminazene aceturate (DIZE), a small molecule ACE2 activator, has been used to evaluate this hypothesis. DIZE (15 mg/kg per day, s.c.) was injected 2 days before MI surgery and continued throughout the study period. MI rats showed a 62% decrease in fractional shortening (%; control, 51.1±3.2; DIZE alone, 52.1±3.2; MI, 19.1±3.0), a 55% decrease in contractility (dP/dtmax mm Hg/s; control, 9480±425.3; DIZE alone, 9585±597.4; MI, 4251±657.7), and a 27% increase in ventricular hypertrophy (mg/mm; control, 26.5±1.5; DIZE alone, 26.9±1.4; MI, 33.4±1.1). DIZE attenuated the MI-induced decrease in fractional shortening by 89%, improved dP/dtmax by 92%, and reversed ventricular hypertrophy by 18%. MI also significantly increased ACE and angiotensin type 1 receptor levels but decreased ACE2 activity by 40% (control, 246.2±25.1; DIZE alone, 254.2±20.6; MI, 148.9±29.2; RFU/min), which was reversed by DIZE treatment. Thus, DIZE treatment decreased the infarct area, attenuated LV remodeling post-MI, and restored normal balance of the cardiac renin–angiotensin system. In addition, DIZE treatment increased circulating endothelial progenitor cells, increased engraftment of cardiac progenitor cells, and decreased inflammatory cells in peri-infarct cardiac regions. All of the beneficial effects associated with DIZE treatment were abolished by C-16, an ACE2 inhibitor. Collectively, DIZE and DIZE-like small molecules may represent promising new therapeutic agents for MI.

  • angiotensin-converting enzyme 2
  • diminazene
  • macrophages
  • myocardial infarction
  • stem cells

Introduction

The renin–angiotensin system (RAS) plays a critical role in maintaining cardiovascular homeostasis. Angiotensin-converting enzyme 2 (ACE2) metabolizes angiotensin II (AngII) into the heptapeptide angiotensin-(1–7) (Ang-[1–7]),1,2 thereby maintaining a balance between the deleterious axis (ACE/AngII/angiotensin type 1 receptor [AT1R]) and the vasoprotective axis (ACE2/Ang-(1–7)/Mas receptor [MasR]) of the RAS. ACE inhibitors and angiotensin receptor blockers are leading pharmacotherapeutic interventions for cardiovascular diseases.3–5 It has been demonstrated that the use of these agents to inhibit the deleterious axis of the RAS leads to an upregulation of ACE2.6

ACE2 modulates cardiac function and could be a potential therapeutic target for cardiovascular diseases, on the basis of the following evidences: (1) ACE2 and Ang-(1–7) levels are increased as a compensatory mechanism in the heart after myocardial infarction (MI) in both humans and rats7–9; (2) we and others have demonstrated that cardiac overexpression of ACE2 renders protection against ischemia-induced cardiac pathophysiology10,11; (3) overexpression of Ang-(1–7) protects the heart from the ischemic-induced cardiac dysfunction12; (4) we have previously demonstrated that a small molecule, XNT (1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one), possessing the potential to activate ACE2, prevents cardiac remodeling in spontaneously hypertensive rats.13 Collectively, these findings have led several groups to propose that administration of recombinant ACE2 could be a potential therapeutic strategies for the treatment of heart failure.14,15

Recently, diminazene aceturate (DIZE), another US Food and Drug Administration–listed small molecule used as an antitrypanosomal drug, has been shown to exert off-target effects of activating ACE2.16 We have recently demonstrated that DIZE treatment renders cardioprotective effects and improves angiogenic progenitor cell functions in rat model of pulmonary hypertension.17 This complied with the fact that current standard treatments for MI cannot efficiently improve cardiac function and prevent further damage to the myocardium. We decided to evaluate the effects of DIZE on ischemic-induced cardiac pathophysiology. Our observations demonstrate that DIZE treatment prevents MI-induced cardiac pathophysiology, thus providing us an opportunity to explore the therapeutic potential of this compound in ischemic heart disease and heart failure.

Material and Methods

All experimental protocols are presented in the Methods in the online-only Data Supplement.

Results

DIZE Treatment Prevents the MI-Induced Left Ventricular Dysfunction, and C-16 Abolishes the Protective Effects of DIZE

MI caused a 62% reduction in fractional shortening (Figure 1A) and a 27% increase in ventricular hypertrophy (Figure 1B), which were significantly prevented by DIZE treatment. Measurement of cardiac hemodynamic functions in MI animals revealed higher left ventricular end diastolic pressure and decreased dP/dtmax and dP/dtmin compared with normal and DIZE controls, which were restored by DIZE treatment (Figure 1C–1E). We had hypothesized that these beneficial effects of DIZE are associated with the activation of endogenous cardiac ACE2. Therefore, we coadministered C-16, a selective ACE2 inhibitor,17 along with DIZE. Four weeks of cotreatment with C-16 abolished the improvements in cardiac function produced by DIZE (Figure 1A–1E). In contrast to these beneficial effects on cardiac pathophysiology, DIZE treatment did not alter systolic blood pressure (Figure 1F).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Diminazene aceturate (DIZE) treatment prevents the development of myocardial infarction (MI)–induced heart failure and associated cardiac hypertrophy. Measurement of (A) fractional shortening and (B) ventricular hypertrophy reflected by the ratio of ventricular weight to tibia length (VW/TL), (C) dP/dtmax, (D) dP/dtmin, (E) left ventricular end diastolic pressure (LVEDP), and (F) systolic blood pressure (SBP). Data represent mean±SEM. *MI (M), MI+DIZE (M+D), and MI+DIZE+C16 (M+D+C) vs Control (Con) and DIZE (D); #M+D vs M and M+D+C;**M and M+D+C vs Con, D, and M+D; P<0.001.

DIZE Treatment Alters Cardiac RAS Levels

mRNA levels of ACE and ACE2 and protein levels of AT1R and MasR were measured to determine whether DIZE treatment shifts the balance from deleterious to vasoprotective axis of the RAS. Cardiac ACE mRNA increased by 2-fold, whereas ACE2 mRNA decreased 2-fold in MI animals (Figure 2A and 2B). DIZE treatment reduced ACE mRNA and significantly elevated ACE2 mRNA in the MI animals. As a result, the ratio of the mRNA levels of ACE2/ACE was 2-fold higher in DIZE-treated MI hearts (Figure 2C). MI induced 2-fold increase in ACE activity, although this activity in DIZE-treated MI hearts was not significantly different from the control and DIZE-treated hearts (Figure 2D). In contrast, ACE2 activity was modestly decreased in the peri-infarct area of the MI hearts, and DIZE treatment resulted in 2.5-fold increase in this activity (Figure 2E). Plasma ACE2 activity was slightly lowered in MI animals and significantly increased by DIZE treatment, which was abolished by C-16 (Figure 2F). Moreover, Western blot analysis demonstrated a 1.9-fold increase in AT1R protein levels (Figure 2G) and a moderate increase in MasR (Figure 2H) in the MI group. DIZE treatment significantly inhibited the increase in AT1R. These changes induced by DIZE were blocked by treatment with C-16. However, DIZE treatment did not significantly alter the increase in MasR compared with the MI group.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Diminazene aceturate (DIZE) modulates cardiac renin–angiotensin system. Relative change in cardiac mRNA levels of the angiotensin-converting enzyme (ACE; A) and ACE2 (B) genes, ACE2/ACE ratio (C), cardiac ACE activity (D), cardiac ACE2 activity (E), and plasma ACE2 activity (F). Representative Western blot showing protein expression of AT1R (G) and Mas receptor (MasR) (H). Data represent mean±SEM. **MI (M) and MI+DIZE+C16 (M+D+C) vs control (Con), D, and M+D; *M, M+D, and M+D+C vs Con and D; #M+D vs M and M+D+C; ***M+D vs Con, M, and M+D+C; %D vs M and M+D+C; P<0.05. AT1R indicates angiotensin type 1 receptor.

DIZE Treatment Increases Numbers of Cardiac Progenitor Cells and Circulating Endothelial Progenitor Cells

Our next objective was to determine whether the reparative capacities of DIZE are because of its effects on progenitor cells. Thus, we determined the levels of circulating endothelial progenitor cells (EPCs) and Islet-1 (a marker for cardiac progenitor cells [CPCs]). We observed a 2-fold increase in the CPCs in the peri-infarct region of the DIZE-treated ischemic heart (Figure 3A and 3B). This increase in the number of CPCs suggests a higher regenerative potential in the hearts from DIZE-treated animals. Moreover, the number of circulating EPCs was also increased by 48% in the DIZE-treated animals over that observed in the MI group (Figure 3C). Cotreatment of DIZE animals with C-16 abolished both increases in the CPCs and in the EPCs.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Diminazene aceturate (DIZE) increases the number of cardiac progenitor cells in the peri-infarct area of the heart and circulating rat endothelial progenitor cell (EPCs). Islet-1 is predominantly found in the nuclei. Representative immunofluorescence images of Islet-1+ cells (red fluorescence, indicated by yellow arrowhead). The nuclei were stained with DAPI (4',6-diamidino-2-phenylindol; blue fluorescence). Islet-1 level was also quantified by Western blot (A and B). The number of rat EPCs (CD4−/5−/8−/90+) in the blood was also measured using flow cytometry (C). Data are expressed as mean±SEM; **MI (M) and MI+DIZE+C16 (M+D+C) vs control (Con), D, and M+D; $M+D vs M+D+C; P<0.05. Scale bar, 20 μm.

DIZE Treatment Decreases Infiltration of Macrophages in the Peri-Infarct Area of the Heart and Modulates Proinflammatory Cytokines

Infiltration of macrophage in the peri-infarct area of the heart is associated with MI.18 Thus, we examined whether DIZE treatment would influence this process. DIZE treatment significantly prevented the infiltration of CD68+ cells (a marker for macrophages; Figure 4, top panel). Western blot analysis showed that CD68 immunoreactivity in MI hearts was increased by 46%, which was completely attenuated by DIZE treatment (Figure 4A and 4B). Interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α) mRNA levels were examined next to determine whether the beneficial effects of DIZE on cardiac hemodynamic were associated with changes in the proinflammatory cytokines. As expected, MI resulted in 2.5- and 3-fold increases in IL-1β and TNF-α, respectively (Figure 4C and 4D). DIZE treatment alone did not affect these cytokines in control animals. However, DIZE treatment in the MI animals prevented the increase in these cytokines, which further supported the anti-inflammatory effects of DIZE. C-16 blocked all the anti-inflammatory effects of DIZE (Figure 4).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Diminazene aceturate (DIZE) decreases the number of infiltrated macrophage and modulates cardiac proinflammatory cytokines. Representative immunofluorescence images of CD68 antibody–positive cells (red fluorescence) and nuclei (blue). CD68 was quantified by Western blot (A and B). Relative mRNA levels of IL-1β (C) and TNF-α (D). Data are expressed as mean±SEM; **MI (M) and MI+DIZE+C16 (M+D+C) vs control (Con), D, and M+D; P<0.05. Scale bar, 20 μm.

DIZE Treatment Decreases Infarct Area and MI-Induced Apoptosis

DIZE treatment decreased the infarct size by 50% (Figure S1A in the online-only Data Supplement). Next, we examined whether DIZE exerts antiapoptotic effects in response to ischemia. Heart sections of the MI group showed 6-fold increase in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining, which was prevented by DIZE treatment (Figure S1B). C-16 treatment abolished all the effects produced by DIZE (Figure S1).

DIZE Treatment Prevents the MI-Induced Loss of Capillary Density

A significant reduction (1-fold) in capillary density was observed in MI hearts. DIZE treatment alone did not alter capillary density; however, DIZE treatment in the MI animals significantly prevented the decrease in the capillary density of the MI group (Figure S2).

Discussion

Our study is significant in that it provides evidence that DIZE, an ACE2 activator offers impressive protection against MI by preserving fractional shortening, attenuating the increase in LVEDP, preventing the dysfunctional changes in dP/dt, and decreasing infarct size and apoptosis. This treatment also modulates the RAS in a positive manner, reduces inflammatory processes, and increases the engraftment of CPCs and circulating EPCs. All these beneficial effects were blocked by C-16.

The imbalance in the RAS as a result of an increase in the vasodeleterious (ACE/AngII/AT1R) axis and a decrease in the vasoprotective (ACE2/Ang-(1–7)/MasR) axis has been proposed to be critical in the development and establishment of cardiac pathophysiology.19,20 ACE2 expression is upregulated at the beginning of the MI as a compensatory mechanism8 and then significantly decreased at heart failure stage.21 Because DIZE is administered before the injury is induced, it protects heart function and thus prevents the ACE2 downregulation. It is also possible that DIZE modulates ACE2 expression and acts in a positive feedback manner because DIZE has been found to be able to bind DNA.22 Thus, we hypothesize that restoring this imbalance by the activation of endogenous ACE2 could provide protection against cardiac damage. This study provides evidence in support of this concept and confirms the protective role of the vasoprotective axis because all the dysfunctional and pathological parameters were prevented by the ACE2 activator.

It has been shown that ACE2 overexpression in the human umbilical vein endothelial cells leads to an increase in tube formation and can promote endothelial cell migration in vitro, and ACE2 can promote capillary formation and neovessel maturation in vivo.23,24 DIZE, as an ACE2 activator, may also promote angiogenesis and exert its effects via Ang-(1–7). Ang-(1–7) also has been shown to directly act on hematopoietic progenitor cells and modulate their function.25,26 In the present study, DIZE causes an increase in CPCs homing to the peri-infarct area of the ischemic heart, increases circulating EPCs, and restores capillary density, all of which are correlated with an improvement of cardiac function. Our study and others indicate that the ACE2/Ang-(1–7)/MasR axis induces mechanisms that are pivotal for regenerative therapy, and further studies on the signaling pathways activated by DIZE in progenitor cells are warranted.

Elevated levels of proinflammatory cytokines, such as IL-1β and TNF-α, contribute to the development and progression of ischemic injury.27,28 The ACE2/Ang-(1–7)/MasR axis possesses an anti-inflammatory role.29 Our observation that DIZE prevents increases in proinflammatory cytokines, and macrophage cells further supports the importance of this compound in influencing many pathological events, directly and indirectly. This is supported by our previous observations that overexpression of Ang-(1–7) and DIZE treatment decreases pulmonary proinflammatory cytokines in models of lung disease.17,30

In summary, our study illustrates that DIZE treatment preserves cardiac function and attenuates cardiac remodeling post-MI. The beneficial effects of DIZE may be a result of preventing the imbalance of the RAS observed post-MI, subsequently modulating various proinflammatory cytokines associated with MI injury, decreasing the infiltration of macrophages associated with cardiac ischemia, and increasing the homing of CPCs and mobilizing EPCs.

Finally, it is pertinent to point out that we have used DIZE as a compound to test this proof of concept. DIZE has been shown to exert toxic effects in some studies31–33 and may not be the pharmacodynamically ideal molecule for translational studies. Nonetheless, the study is relevant in that it provides evidence that the chemical structure resides in DIZE has the potential to activate ACE2, provide beneficial outcomes in MI-induced cardiac pathophysiology, and form the basis to develop structure similar and safe compounds.

Perspectives

Recently, Oudit and Penninger14 have suggested that recombinant ACE2 can be used as a novel therapy for heart failure. However, the application of recombinant ACE2 protein for MI is limited by its peptide nature and possible metabolic degradation if administrated orally. The use of synthetic small molecules, such as DIZE, or other compounds that are ACE2 activators, could circumvent these issues. Thus, current observations support the concept that targeting of the cardiac ACE2/Ang-(1–7)/MasR axis using a small molecule could hold novel therapeutic strategy in the treatment of MI and its associated complications.

Acknowledgments

We acknowledge Marda Jorgensen and Neal A. Benson for their technical assistance and help with immunohistochemistry and flow cytometry.

Sources of Funding

This work was supported by National Institutes of Health grants HL056921 and HL102033 awarded to M.K. Raizada and M.J. Katovich.

Disclosures

None.

Footnotes

  • The online-only Data Supplement is available with this article at http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA.113.01337/-/DC1.

  • Received March 4, 2013.
  • Revision received March 22, 2013.
  • Accepted July 22, 2013.
  • © 2013 American Heart Association, Inc.

References

  1. 1.↵
    1. Tipnis SR,
    2. Hooper NM,
    3. Hyde R,
    4. Karran E,
    5. Christie G,
    6. Turner AJ
    . A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238–33243.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Vickers C,
    2. Hales P,
    3. Kaushik V,
    4. Dick L,
    5. Gavin J,
    6. Tang J,
    7. Godbout K,
    8. Parsons T,
    9. Baronas E,
    10. Hsieh F,
    11. Acton S,
    12. Patane M,
    13. Nichols A,
    14. Tummino P
    . Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838–14843.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Jalil JE,
    2. Janicki JS,
    3. Pick R,
    4. Weber KT
    . Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension. Response to captopril. Am J Hypertens. 1991;4(1 Pt 1):51–55.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Thürmann PA,
    2. Kenedi P,
    3. Schmidt A,
    4. Harder S,
    5. Rietbrock N
    . Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98:2037–2042.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Ferreira AJ,
    2. Shenoy V,
    3. Yamazato Y,
    4. Sriramula S,
    5. Francis J,
    6. Yuan L,
    7. Castellano RK,
    8. Ostrov DA,
    9. Oh SP,
    10. Katovich MJ,
    11. Raizada MK
    . Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:1048–1054.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Ishiyama Y,
    2. Gallagher PE,
    3. Averill DB,
    4. Tallant EA,
    5. Brosnihan KB,
    6. Ferrario CM
    . Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970–976.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Averill DB,
    2. Ishiyama Y,
    3. Chappell MC,
    4. Ferrario CM
    . Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation. 2003;108:2141–2146.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Burrell LM,
    2. Risvanis J,
    3. Kubota E,
    4. Dean RG,
    5. MacDonald PS,
    6. Lu S,
    7. Tikellis C,
    8. Grant SL,
    9. Lew RA,
    10. Smith AI,
    11. Cooper ME,
    12. Johnston CI
    . Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005;26:369–75;discussion 322.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Ohtsuki M,
    2. Morimoto S,
    3. Izawa H,
    4. Ismail TF,
    5. Ishibashi-Ueda H,
    6. Kato Y,
    7. Horii T,
    8. Isomura T,
    9. Suma H,
    10. Nomura M,
    11. Hishida H,
    12. Kurahashi H,
    13. Ozaki Y
    . Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int J Cardiol. 2010;145:333–334.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Der Sarkissian S,
    2. Grobe JL,
    3. Yuan L,
    4. Narielwala DR,
    5. Walter GA,
    6. Katovich MJ,
    7. Raizada MK
    . Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension. 2008;51:712–718.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Zhao YX,
    2. Yin HQ,
    3. Yu QT,
    4. et al
    . ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther. 2010;21:1545–1554.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Qi Y,
    2. Shenoy V,
    3. Wong F,
    4. Li H,
    5. Afzal A,
    6. Mocco J,
    7. Sumners C,
    8. Raizada MK,
    9. Katovich MJ
    . Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. Exp Physiol. 2011;96:863–874.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Hernández Prada JA,
    2. Ferreira AJ,
    3. Katovich MJ,
    4. Shenoy V,
    5. Qi Y,
    6. Santos RA,
    7. Castellano RK,
    8. Lampkins AJ,
    9. Gubala V,
    10. Ostrov DA,
    11. Raizada MK
    . Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51:1312–1317.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Oudit GY,
    2. Penninger JM
    . Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr Heart Fail Rep. 2011;8:176–183.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Iwata M,
    2. Cowling RT,
    3. Yeo SJ,
    4. Greenberg B
    . Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol. 2011;51:542–547.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Kulemina LV,
    2. Ostrov DA
    . Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen. 2011;16:878–885.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Shenoy V,
    2. Gjymishka A,
    3. Jarajapu YP,
    4. et al
    . Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013;187:648–657.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Lambert JM,
    2. Lopez EF,
    3. Lindsey ML
    . Macrophage roles following myocardial infarction. Int J Cardiol. 2008;130:147–158.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Ferrario CM,
    2. Chappell MC,
    3. Tallant EA,
    4. Brosnihan KB,
    5. Diz DI
    . Counterregulatory actions of angiotensin-(1-7). Hypertension. 1997;30(3 Pt 2):535–541.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Ferreira AJ,
    2. Jacoby BA,
    3. Araújo CA,
    4. Macedo FA,
    5. Silva GA,
    6. Almeida AP,
    7. Caliari MV,
    8. Santos RA
    . The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292:H1113–H1119.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Sumit K,
    2. Lie G,
    3. Irving Z
    . Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure. J Appl Physiol. 2010;108:923–932.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Pilch DS,
    2. Kirolos MA,
    3. Liu X,
    4. Plum GE,
    5. Breslauer KJ
    . Berenil [1,3-bis(4’-amidinophenyl)triazene] binding to DNA duplexes and to a RNA duplex: evidence for both intercalative and minor groove binding properties. Biochemistry. 1995;34:9962–9976.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Lovren F,
    2. Pan Y,
    3. Quan A,
    4. Teoh H,
    5. Wang G,
    6. Shukla PC,
    7. Levitt KS,
    8. Oudit GY,
    9. Al-Omran M,
    10. Stewart DJ,
    11. Slutsky AS,
    12. Peterson MD,
    13. Backx PH,
    14. Penninger JM,
    15. Verma S
    . Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008;295:H1377–H1384.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Jarajapu YP,
    2. Bhatwadekar AD,
    3. Caballero S,
    4. Hazra S,
    5. Shenoy V,
    6. Medina R,
    7. Kent D,
    8. Stitt AW,
    9. Thut C,
    10. Finney EM,
    11. Raizada MK,
    12. Grant MB
    . Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors. Diabetes. 2013;62:1258–1269.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Heringer-Walther S,
    2. Eckert K,
    3. Schumacher SM,
    4. Uharek L,
    5. Wulf-Goldenberg A,
    6. Gembardt F,
    7. Fichtner I,
    8. Schultheiss HP,
    9. Rodgers K,
    10. Walther T
    . Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica. 2009;94:857–860.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Wang Y,
    2. Qian C,
    3. Roks AJ,
    4. Westermann D,
    5. Schumacher SM,
    6. Escher F,
    7. Schoemaker RG,
    8. Reudelhuber TL,
    9. van Gilst WH,
    10. Schultheiss HP,
    11. Tschöpe C,
    12. Walther T
    . Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail. 2010;3:286–293.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Testa M,
    2. Yeh M,
    3. Lee P,
    4. Fanelli R,
    5. Loperfido F,
    6. Berman JW,
    7. LeJemtel TH
    . Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28:964–971.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Torre-Amione G,
    2. Kapadia S,
    3. Benedict C,
    4. Oral H,
    5. Young JB,
    6. Mann DL
    . Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–1206.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Ferrario CM,
    2. Jessup J,
    3. Chappell MC,
    4. Averill DB,
    5. Brosnihan KB,
    6. Tallant EA,
    7. Diz DI,
    8. Gallagher PE
    . Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–2610.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Shenoy V,
    2. Ferreira AJ,
    3. Qi Y,
    4. Fraga-Silva RA,
    5. Diez-Freire C,
    6. Dooies A,
    7. Jun JY,
    8. Sriramula S,
    9. Mariappan N,
    10. Pourang D,
    11. Venugopal CS,
    12. Francis J,
    13. Reudelhuber T,
    14. Santos RA,
    15. Patel JM,
    16. Raizada MK,
    17. Katovich MJ
    . The ACE2/Ang-(1–7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2010;182:1065–1072.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Ruebush TK 2nd.,
    2. Rubin RH,
    3. Wolpow ER,
    4. Cassaday PB,
    5. Schultz MG
    . Neurologic complications following the treatment of human Babesia microti infection with diminazene aceturate. Am J Trop Med Hyg. 1979;28:184–189.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Homeida AM,
    2. El Amin EA,
    3. Adam SE,
    4. Mahmoud MM
    . Toxicity of diminazene aceturate (Berenil) to camels. J Comp Pathol. 1981;91:355–360.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Sharma SP,
    2. Bansal GC
    . Chemoprophylaxis with diminazene aceturate in experimental Babesia bigemina infection in cattle. Res Vet Sci. 1984;37:126–127.
    OpenUrlPubMed

Novelty and Significance

What Is New?

  • This study demonstrates, for the first time, that chronic administration of ACE2 activator (diminazene aceturate [DIZE]) attenuated the myocardial infarction–induced cardiac dysfunction.

  • DIZE increased the number of circulating endothelial progenitor cells and cardiac progenitor cells and decreased the macrophage infiltration in the ischemic myocardium, which reveals a previously unidentified role of DIZE in modulating progenitor cells and the regulation of inflammation.

What Is Relevant?

  • It is significant that chronic activation of endogenous ACE2 by DIZE or as such attenuated MI-induced cardiac pathophysiology, which provides a new therapeutic approach for ischemic heart diseases and related cardiovascular disorders.

Summary

DIZE attenuated MI-induced cardiac pathophysiology through modulating the gene expression of the RAS and inflammatory cytokines, increasing EPCs and CPCs, and suppressing macrophage infiltration.

View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
October 2013, Volume 62, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Introduction
    • Material and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
    • What Is New?
    • What Is Relevant?
    • Summary
  • Figures & Tables
  • Supplemental Materials
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Diminazene Aceturate Enhances Angiotensin-Converting Enzyme 2 Activity and Attenuates Ischemia-Induced Cardiac PathophysiologyNovelty and Significance
    YanFei Qi, Juan Zhang, Colleen T. Cole-Jeffrey, Vinayak Shenoy, Andrew Espejo, Mina Hanna, Chunjuan Song, Carl J. Pepine, Michael J. Katovich and Mohan K. Raizada
    Hypertension. 2013;62:746-752, originally published September 11, 2013
    https://doi.org/10.1161/HYPERTENSIONAHA.113.01337

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Diminazene Aceturate Enhances Angiotensin-Converting Enzyme 2 Activity and Attenuates Ischemia-Induced Cardiac PathophysiologyNovelty and Significance
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Diminazene Aceturate Enhances Angiotensin-Converting Enzyme 2 Activity and Attenuates Ischemia-Induced Cardiac PathophysiologyNovelty and Significance
    YanFei Qi, Juan Zhang, Colleen T. Cole-Jeffrey, Vinayak Shenoy, Andrew Espejo, Mina Hanna, Chunjuan Song, Carl J. Pepine, Michael J. Katovich and Mohan K. Raizada
    Hypertension. 2013;62:746-752, originally published September 11, 2013
    https://doi.org/10.1161/HYPERTENSIONAHA.113.01337
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Genetics
    • Gene Expression & Regulation
  • Intervention, Surgery, Transplantation
    • Pharmacology
  • Basic, Translational, and Clinical Research
    • Animal Models of Human Disease

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured